MaaT Pharma, SA
5 Place Charles
About MaaT Pharma, SAMaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.
Co-Founder and CEO: Herve´ Affagard
Co-Founder and Non Executive President of the Board: Dr Pierre Belichard
Co-Founder: Mr. Joël Doré
Co-Founder: Mr. Pierre Rimbaud
Please click here for Auspherix's job opportunities.
Please click here for MaaT Pharma's pipeline.
33 articles with MaaT Pharma, SA
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
MaaT Pharma Announces First Positive DSMB Safety Review for Phase Ib CIMON Trial Testing Its Microbiome Ecosystem Therapy Capsule Formulation in AML Patients
Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of second patient cohort
MaaT Pharma Presents Positive Updated Results with its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute GvHD at ASH 2020 Annual Meeting
Data showed MaaT013 to be safe and effective in 29 heavily pre-treated and immunocompromised gastrointestinal (GI) acute Graft-versus-Host-Disease (aGvHD) patients
MaaT Pharma Announces Series B Extension and Final Closing with Total of €25 Million ($29.5 Million)
Additional proceeds will be used primarily to accelerate the development of a proprietary fermentation process to design targeted, full-ecosystem, large-scale, microbiome-based products
MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic in Oral Presentation at 62nd American Society of Hematology (ASH) Annual Meeting
Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe, demonstrating positive impact
MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic
Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy
9/3/2020Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT
MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46 th Annual Meeting of the EBMT -- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013, MaaT Pharma’s full-ecosystem microbiota biotherapeutic, as part of a compassionate use program -- -- MaaT013 provided positive impact with satisfactory safety profile in al
MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation
MaaT Pharma Appoints Claude Bertrand, Servier’s Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg
MaaT Pharma announced the appointment of Claude Bertrand, PharmD, PhD, as an independent member to the company’s Board of Directors and welcomes John Weinberg, MD, as new Chief Medical Officer.
MaaT Pharma strengthens management team adding strategic business development and product marketing expertise
MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications
MaaT Pharma announced today the appointment of leading international experts in the field of microbiome research, hemato-oncology, infectiology, immunology, pharmacology, and clinical trial methodology to its newly-formed Scientific Advisory Board (SAB) focused on the treatment of Graft versus Host Disease (GvHD). The SAB will serve as a resource to advise MaaT Pharma on its scientific, regulatory and clinical development
2/6/2020Pharma and life science companies from across the globe provide updates on their pipelines and businesses.
MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics
Funding enables expansion of clinical program to include additional cancer indications and development of a capsule formulation of MaaT Pharma’s full-ecosystem therapeutic
MaaT Pharma Announces the Presentation of Positive Data with Its Lead Microbiome Biotherapeutic in Intestinal-Predominant Acute Graft-versus-Host-Disease at the ASH 2019 Annual Meeting
MaaT Pharma’s full-ecosystem microbiota biotherapeutic provided positive impact with satisfactory safety profile in eight patients with advanced stages of GI aGvHD
MaaT Pharma to Present Initial Results with its Lead Microbiota Biotherapeutic in Intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting
Pooled-donor full ecosystem microbiota biotherapeutic reported safe in eight patients treated
9/13/2019Biotech and pharma companies strengthen their leadership teams with new appointments.
MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform, GutPrint
MaaT Pharma announced the appointment of Jean-Marc Renard, MS, MBA, as Chief Business Officer and Emmanuel Prestat, PhD as Computational Biology Manager.
MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute GvHD with no safety concerns occurring within the study
5/23/2019Biopharma companies from across Europe share pipeline and strategy updates.